London (UK) January 23rd , 2025 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), is a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments. Vidac Parma Holding PLC is proud to announce that its Chairman and CEO, Dr. Max Herzberg, has been invited to speak at the “Brain Cancer Data and Tech Innovation” meeting at the Google Campus in Tel Aviv on January 27, 2025. This event brings together leading experts to discuss groundbreaking advancements in brain cancer research and technology. Dr. Herzberg’s participation comes at a pivotal time as Vidac Parma Holding has recently achieved important milestones in the systemic delivery development of its drug candidate, VDA1102. Notably, VDA1102 has demonstrated remarkable efficacy against isolated ex-vivo rare human pediatric brain tumors, which have historically posed significant treatment challenges. The overarching challenge in treating brain tumors lies in their metabolic characteristics, particularly the pronounced Warburg Effect of hyperglycolysis. Dr. Herzberg highlighted that the unique mode of action of VDA1102 effectively reverses these metabolic pathways, positioning it as a promising therapeutic option. “Systemic delivery of VDA1102 opens up a whole new realm of opportunities for helping patients,” stated Dr. Herzberg. “We have observed positive responses from various tumor types to our products and are strategically focusing on several urgent cases with no alternative treatments currently available. Our advancements in developing a systemic delivery method represent a significant step forward in our commitment to addressing these critical medical needs.” Vidac Pharma Holding remains dedicated to pioneering therapeutic solutions in both Onco dermatology for which it is at advanced clinical stage and explore brain cancer and other malignancies, and Dr. Herzberg’s participation in this meeting underscores the company's unique approach in the field.
For more information please contact:
Vidac Pharma Holding Plc
Dr Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom
http://www.vidacpharma.com/
investors@vidacpharma.com
+972-54-4257381
About Vidac Pharma
Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper-glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase 2 metabolic checkpoint (HK2) in cancer cells, to renormalize tumor microenvironment and selectively provoke their programmed death, without affecting surrounding normal tissue. VDA-1102, a first drug candidate of Vidac Pharma has shown to be effective against advanced Actinic Keratosis (AK), while interim results in Cutaneous T-cell Lymphoma (CTCL) yielded a positive effect in Phase 2 trials in humans.
Important information
The information in this press release does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only. The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.